Paratek Pharmaceuticals Inc (NASDAQ:PRTK) – Analysts at G.Research lowered their FY2024 earnings per share estimates for Paratek Pharmaceuticals in a research report issued to clients and investors on Thursday, June 25th. G.Research analyst K. Kedra now expects that the specialty pharmaceutical company will post earnings per share of $0.90 for the year, down from their previous estimate of $0.95.

Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings data on Monday, May 11th. The specialty pharmaceutical company reported ($0.66) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.80) by $0.14. Paratek Pharmaceuticals had a negative net margin of 528.28% and a negative return on equity of 5,327.73%. The business had revenue of $7.92 million during the quarter, compared to the consensus estimate of $7.75 million.

Several other research firms also recently commented on PRTK. Zacks Investment Research upgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.50 price objective for the company in a research note on Tuesday, June 23rd. Wedbush reissued an “outperform” rating on shares of Paratek Pharmaceuticals in a report on Monday, March 9th. Finally, ValuEngine raised shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, April 2nd. Eight equities research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and an average target price of $15.90.

NASDAQ:PRTK opened at $5.11 on Monday. Paratek Pharmaceuticals has a 12 month low of $2.50 and a 12 month high of $5.89. The firm has a fifty day simple moving average of $4.58 and a 200-day simple moving average of $4.02. The company has a market capitalization of $208.75 million, a P/E ratio of -1.46 and a beta of 1.54.

In other Paratek Pharmaceuticals news, insider Randall B. Brenner sold 6,198 shares of Paratek Pharmaceuticals stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $4.75, for a total value of $29,440.50. Following the completion of the transaction, the insider now owns 130,813 shares of the company’s stock, valued at $621,361.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Michael Bigham sold 12,250 shares of Paratek Pharmaceuticals stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $4.68, for a total transaction of $57,330.00. Following the completion of the transaction, the chairman now directly owns 542,167 shares of the company’s stock, valued at approximately $2,537,341.56. The disclosure for this sale can be found here. Insiders sold 32,709 shares of company stock valued at $154,510 in the last ninety days. 8.30% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. grew its position in shares of Paratek Pharmaceuticals by 3.7% in the first quarter. BlackRock Inc. now owns 2,408,849 shares of the specialty pharmaceutical company’s stock valued at $7,588,000 after purchasing an additional 84,937 shares during the period. Rock Springs Capital Management LP grew its position in shares of Paratek Pharmaceuticals by 307.0% in the first quarter. Rock Springs Capital Management LP now owns 1,526,310 shares of the specialty pharmaceutical company’s stock valued at $4,808,000 after purchasing an additional 1,151,310 shares during the period. General American Investors Co. Inc. grew its position in shares of Paratek Pharmaceuticals by 24.7% in the first quarter. General American Investors Co. Inc. now owns 803,184 shares of the specialty pharmaceutical company’s stock valued at $2,530,000 after purchasing an additional 158,861 shares during the period. State Street Corp grew its position in shares of Paratek Pharmaceuticals by 0.8% in the fourth quarter. State Street Corp now owns 679,099 shares of the specialty pharmaceutical company’s stock valued at $2,737,000 after purchasing an additional 5,320 shares during the period. Finally, Goldman Sachs Group Inc. grew its position in shares of Paratek Pharmaceuticals by 157.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 341,322 shares of the specialty pharmaceutical company’s stock valued at $1,376,000 after purchasing an additional 208,755 shares during the period. Institutional investors and hedge funds own 43.41% of the company’s stock.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris.

Recommended Story: Range Trading

Earnings History and Estimates for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.